NODTHERA
NodThera is a Cambridge (UK) headquartered biotech engaged in innate immune/ inflammasome research. Their leading project is focused on developing inhibitors of the NLRP3 inflammasome for the treatment of inflammatory and neuroinflammatory diseases.
NODTHERA
Industry:
Biotechnology Health Care Life Science
Founded:
2016-01-01
Address:
Little Chesterford, Essex, United Kingdom
Country:
United Kingdom
Website Url:
http://www.nodthera.com
Total Employee:
11+
Status:
Active
Contact:
+44 (0) 1223 608130
Email Addresses:
[email protected]
Total Funding:
95 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome
Similar Organizations
1859
1859 is a biotechnology company focusing on the discovery and development of next-generation therapeutics.
Apeiron Biologics
Apeiron Biologics is a biotech company that focuses on the discovery and development of novel cancer immunotherapies.
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Centauri Therapeutics
Centauri Therapeutics is a UK-based biotechnology company focused on the discovery and development of life threatening diseases.
DelphiTest GmbH
DelphiTest core technology capitalizes on the revolutionary development of DNA analysis.
Diomune
Diomune is a biotechnology company specialized in research and development of new immunological treatments for human and animal.
Alumis
Alumis is a precision medicine company focused on the discovery, development and treatment of autoimmune disorders.
Kiq
Kiq is a privately held, biotechnology company focused on the discovery and development of precision kinase inhibitors.
Nokad
Nokad is a biotechnology company that focuses on the discovery and development of new diagnostic strategies for cardiovascular diseases.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
RNAimmune
RNAimmune is a biopharmaceutical company specializing in the discovery and development of mRNA-based therapeutics and vaccines.
Suvica
Suvica is a biotechnology company that is focused on the discovery and development of small molecules for the treatment of cancer.
Toscana Biomarkers
Toscana Biomarkers is a research and development company dedicated to the discovery and validation of new tests for diagnosis.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Walden Biosciences
Walden Biosciences is a biotechnology company focused on transforming the treatment of kidney disease.
Current Advisors List
Current Employees Featured
Investors List
5AM Ventures
5AM Ventures investment in Series B - NodThera
Novo Ventures
Novo Ventures investment in Series B - NodThera
Sofinnova Partners
Sofinnova Partners investment in Series B - NodThera
F-Prime Capital
F-Prime Capital investment in Series B - NodThera
Epidarex Capital
Epidarex Capital investment in Series B - NodThera
Sanofi Ventures
Sanofi Ventures investment in Series B - NodThera
Cowen Healthcare Investments
Cowen Healthcare Investments investment in Series B - NodThera
F-Prime Capital
F-Prime Capital investment in Series A - NodThera
Sofinnova Partners
Sofinnova Partners investment in Series A - NodThera
5AM Ventures
5AM Ventures investment in Series A - NodThera
Official Site Inspections
http://www.nodthera.com Semrush global rank: 5.64 M Semrush visits lastest month: 1.49 K
- Host name: 56.160.211.130.bc.googleusercontent.com
- IP address: 130.211.160.56
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "NodThera"
Home - Nodthera
May 23, 2022 · We are experienced biotech innovators with a vision to make chronic inflammatory disease treatable at its source. Our approach is built on the mounting body of scientific …See details»
About us - Nodthera
May 23, 2022 · Our team of scientists and business leaders truly believe in the potential impact of targeting NLRP3 inflammasome for patients and their families.See details»
NodThera - Crunchbase Company Profile & Funding
NodThera is a Cambridge (UK) headquartered biotech engaged in innate immune/ inflammasome research. Their leading project is focused on developing inhibitors of the NLRP3 inflammasome for the treatment of inflammatory and …See details»
NodThera - Leadership Team - The Org
The Leadership Team at NodThera collaboratively drives the company's strategic vision and operational efficiency, overseeing the discovery and development of innovative biotechnology …See details»
NodThera Announces Appointment of Daniel Swisher as Chief …
May 28, 2024 · He will be responsible for the growing R&D organization and focused on strengthening NodThera’s world-leading position in NLRP3 inflammasome inhibition research, …See details»
Org Chart NodThera - The Official Board
The organizational chart of NodThera displays its 16 main executives including Daniel Swisher, Alan Watt, Alison Strutt and David HarrisonSee details»
NodThera Announces Clinical Progress for Lead NLRP3 …
NodThera is a clinical-stage biotechnology company developing a new class of potent and selective NLRP3 inflammasome inhibitors for the treatment of diseases driven by chronic …See details»
NodThera announces positive first-in-human data for two brain …
BOSTON, MA, June20, 2023 – NodThera, a leading clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, today …See details»
NodThera Announces Appointment of Dr. Thomas Jaecklin as …
BOSTON, MA, February 5, 2024– NodThera, a leading clinical-stage biotech developing brain-penetrant NLRP3 inhibitors to treat chronic inflammatory diseases, today announces the …See details»
NodThera is first to demonstrate reduction in - GlobeNewswire
Jul 11, 2023 · NodThera is a leading clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases. Led by an experienced …See details»
NodThera announces first patients dosed in a Phase Ib/IIa ...
Oct 16, 2023 · NodThera’s trial of its brain-penetrant candidate NT-0796 will explore the potential of central NLRP3 inhibition in the brain to reduce gliosis and other consequences of obesity.See details»
Novo, Sanofi lead $55M round for inflammation player NodThera
Jun 3, 2020 · NodThera is working on drugs that address NLRP3 that is “aberrantly activated,” in the words of Alan Watt, Ph.D., the company’s chief scientific officer, raising $40 million in 2018 …See details»
NodThera Announces Positive Phase 1 Study Readouts for the …
LEXINGTON, MA – September 21, 2022 – NodThera, a clinical-stage biotechnology company developing a new class of potent and selective oral, small molecule NLRP3 inflammasome …See details»
NodThera Publishes Preclinical Data Demonstrating Reversal of …
Feb 19, 2024 · In this latest publication, NodThera’s researchers show for the first time the ability of NT-0796 and NT-0249 to reverse DIO in a murine model, providing comparisons against the …See details»
NodThera Announces Clinical Progress for Lead NLRP3 …
May 10, 2022 · NodThera is a clinical-stage biotechnology company developing a new class of potent and selective NLRP3 inflammasome inhibitors for the treatment of diseases driven by …See details»
NodThera Publishes Preclinical Data Demonstrating Reversal of …
BOSTON, MA, February 19, 2024 – NodThera, a leading clinical-stage biotech developing brain-penetrant NLRP3 inhibitors to treat chronic inflammatory diseases, today announces the …See details»
Discovery of Clinical Candidate NT-0796, a Brain-Penetrant and …
Oct 24, 2023 · We designed a series of ester-substituted carbamate compounds as selective NLRP3 inflammasome inhibitors, leading to NT-0796, an isopropyl ester that undergoes …See details»
NodThera is First to Demonstrate Reduction in Neuroinflammation …
Jul 11, 2023 · NodThera is First to Demonstrate Reduction in Neuroinflammation in the Clinic with Brain Penetrant NLRP3 Inflammasome Inhibitor. NT-0796 demonstrates reduction of multiple …See details»
NodThera Highlights Significant Progress with Advancement of …
Apr 10, 2019 · NodThera is enhancing current understanding of innate immunity and the NLRP3 inflammasome’s role in chronic inflammation to develop a leading platform of small molecule …See details»
NodThera’s NLRP3 Inhibitor NT-0796 Meets Primary Endpoint of ...
Jun 12, 2024 · NodThera’s NLRP3 Inhibitor NT-0796 Meets Primary Endpoint of Inflammation Reversal in Phase Ib/IIa Trial in Obese Subjects with Cardiovascular Risk. – Brain-penetrant …See details»